Table 1.

Patient demographics and baseline characteristics

Characteristics	All Patients (n=13)	Cohort A (n=5)	Cohort B (n=8)
Age
Median (Range)	60 (33 – 76)	60 (34 – 66)	56 (33–76)
Gender
Female	5 (38)	1 (20)	4 (50)
Male	8 (62)	4 (80)	4 (50)
Race
Asian	1 (7.7)	0 (0)	1 (12.5)
White	11 (85)	5 (100)	6 (75)
African American	1 (7.7)	0 (0)	1 (12.5)
Type of AML
Refractory	2 (15)	0 (0)	2 (25)
Relapsed	3 (23)	0 (0)	3 (38)
Untreated	8 (62)	5 (100)	3 (38)
History of CNS disease
Yes	0 (0)	0 (0)	0 (0)
No	13 (100)	5 (100)	8 (100)
History of extramedullary disease
Yes	0 (0)	0 (0)	0 (0)
No	12 (92)	5 (100)	7 (88)
unknown	1 (8)	0 (0)	1 (12)
ELN 2011 Genetic Group
Favorable	2 (15)	0 (0)	2 (25)
Intermediate I	6 (46)	1 (20)	5 (62.5)
Intermediate II	5 (38)	4 (80)	1 (12.5)
FLT3 ITD mutation
Yes	13 (100)	5 (100)	8 (100)
No	0 (0)	0 (0)	0 (0)
FLT3 TKD mutation
Yes	1 (8)	1 (20)	0 (0)
No	12 (92)	4 (80)	8 (100)
CEBPA Mutation
Yes	0 (0)	0 (0)	0 (0)
No	13 (100)	5 (100)	8 (100)
NPM1 mutation
Yes	4 (31)	0 (0)	4 (50)
No	9 (69)	5 (100)	4 (50)
ECOG at baseline (Performance Status)
0	3 (23)	1 (20)	2 (25)
1	9 (69)	4 (80)	5 (62)
2	1 (8)	0 (0)	1 (13)
Prior MDS
Yes	0 (0)	0 (0)	0 (0)
No	13 (100)	5 (100)	8 (100)
Prior MPN
Yes	1 (8)	1 (20)	0 (0)
No	10 (77)	4 (80)	6 (75)
unknown	2 (15)	0 (0)	2 (25)
Bone Marrow Blast
Median (Range)	40 (2 – 88)	40 (23–65)	40 (2–88)
Peripheral Blood Blast
Median (Range)	15 (0 – 88)	15 (7 – 32)	13 (0 – 88)
WBC
Median (Range)	8.3 (0.4 – 126)	5.8 (1.4 – 9.1)	11 (0.4–126)
ANC
Median (Range)	0.4 (0 – 5.5)	0.6 (0.1 – 2.6)	0.3 (0.0 – 5.5)
HGB
Median (Range)	7.5 (7 – 13)	7.4 (7 – 8.7)	8.7 (7.1 – 13)
Platelets
Median (Range)	44 (11 – 340)	57 (29 – 340)	26 (11 – 330)